RedHill Gets Two Notices Of Allowance From USPTO Regarding RHB-104

(RTTNews) - RedHill Biopharma Ltd. (RDHL) said it has received two notices of allowance from the United States Patent and Trademark Office or USPTO regarding its patent application numbers 13/722,395 and 14/271,758 covering RHB-104.

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. It is currently undergoing a first Phase III study for Crohn's disease and a Phase IIa study for multiple sclerosis.

Patent application number 13/722,395, entitled "Methods and Compositions for Treating Inflammatory Bowel Disease", once granted, is expected to be valid until October 2029.

Patent application number 14/271,758 entitled "Methods and Compositions Comprising Rifabutin, Clarithromycin, and Clofazamine", once granted, is expected to be valid until at least February 2029.